^
Association details:
| Biomarker: | KIF5B-RET fusion |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Alecensa (alectinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Selective RET kinase inhibition for patients with RET-altered cancers
Excerpt:
A second patient with KIF5B-RET fusion-positive lung cancer, acquired resistance to alectinib and symptomatic brain metastases experienced a dramatic response in the brain, and her symptoms resolved.
DOI:
10.1093/annonc/mdy137
Test:
